Thursday, August 12, 2021 1:31 PM EDT
Why vaccines may be overrated for COVID-19.
CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma
Contributor's Links:
International Medical Consultants Levolta Pharma Nutent therapeutucs
TWEETS
PERSONAL BLOG
Work Experience
Publications
| Germs of War | |
| Ketan Desai | |
| BookSurge Publishing | |
| 08/21/2002 | |
| A book where bioterrorism meets international intrigue, politics, and religious fundamentalism. |
Latest Comments
Review Of Present Therapies For Covid-19
CYDY is still a garbage company. Nothing has changed there. Dont know why the chart is no longer showing. Must be some software problem at TM
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What is sad is your ignorant pumping. Nothing was done to this stock, it went down as there was no science, no management, no clinical or regulatory path forward. And no, it does not go to show any stock has "unknown things and is unpredictable" - I've been bearish on this for over a year while you were shamelessly pumping.
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Still pumping this garbage? Has failed every study, been scoled by the FDA for lying, has had 25 different firms file lawsuits, lost a distributor in US, and stock is now down to $1.40 or thereabouts. When you started pumping this stock, it was in the $4 range. Have you no shame?
Review Of Present Therapies For Covid-19
Thanks. Your point of placebo is well taken. Often though, it is not true placebo. The design is standard of care plus study drug versus standard of care plus placebo. The patients thus get the minimum of standard of care.
Review Of Present Therapies For Covid-19
Thanks
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.
www.sciencedirect.com/.../S1074761320301837
science.sciencemag.org/content/369/6508/eabc8511
www.thelancet.com/.../fulltext#seccestitle60
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
www.frontiersin.org/.../full
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.